Nathaniel A Cohen
Overview
Explore the profile of Nathaniel A Cohen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
317
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Choi D, Cohen N, Choden T, Cohen R, Rubin D
Inflamm Bowel Dis
. 2023 Jan;
29(10):1658-1661.
PMID: 36715294
No abstract available.
12.
Reicher R, Cohen N, Fishman S, Shnell M
Obes Surg
. 2023 Jan;
33(3):870-878.
PMID: 36689142
Purpose: OAGB is the third most common bariatric surgery. Biliary reflux (BR) is an inherent complication of this unique anatomy, although there is still controversy regarding its significance and long-term...
13.
Garcia N, Cohen N, Rubin D
United European Gastroenterol J
. 2022 Dec;
10(10):1121-1128.
PMID: 36507876
Crohn's disease (CD) is a chronic immune-mediated inflammatory condition which can negatively impact a patient's quality of life. The traditional management strategy for CD has focused on symptomatic control, however,...
14.
Cohen N, Steinberg J, Silfen A, Traboulsi C, Rodriguez T, Singer J, et al.
Dig Dis Sci
. 2022 Oct;
68(4):1464-1472.
PMID: 36242686
Background: Recent real-world effectiveness studies investigating tofacitinib have been encouraging. Questions remain regarding the long-term effectiveness and safety of tofacitinib, effect on endoscopic remission rates, histologic changes, and alterations in...
15.
Cohen N, Kliper E, Zamstein N, Ziv-Baran T, Waterman M, Hodik G, et al.
Dig Dis Sci
. 2022 Oct;
68(2):414-422.
PMID: 36221010
Background: Few data describing pre-diagnosis changes in patients with inflammatory bowel disease (IBD) exist. We aimed to determine if there is a pattern of change in use of health resources,...
16.
Cohen N, Rubin D
Gastrointest Endosc Clin N Am
. 2022 Oct;
32(4):863-873.
PMID: 36202521
This article reviews the latest data concerning the use of advanced therapeutic techniques for endoscopically treating colitis-associated neoplastic lesions and discusses factors associated with improved outcomes.
17.
Cohen N, Dalal S, Choi D, Rubin D
ACG Case Rep J
. 2022 Aug;
9(7):e00832.
PMID: 35919406
Ozanimod has recently received US Food and Drug Administration approval for moderate-to-severe ulcerative colitis. Treatment of acute severe colitis remains a clinical challenge, and although many patients respond to cyclosporine...
18.
Cohen N, Zafer M, Setia N, Anderson M, Sakuraba A, Dalal S, et al.
Dig Dis Sci
. 2022 Jul;
68(3):897-901.
PMID: 35781654
Background: Diagnosis of cytomegalovirus (CMV) colitis in the setting of severe ulcerative colitis (UC) remains a clinical challenge. This study aimed to determine the utility of serum CMV polymerase chain...
19.
Mikolajczyk A, Cohen N, Watson S, Ackerman M, Goeppinger S, Hart J, et al.
Inflamm Bowel Dis
. 2022 Apr;
29(2):222-227.
PMID: 35436339
Introduction: Treatment of ulcerative colitis (UC) now includes mucosal healing. Adoption of histologic end points is hindered by a lack of evidence guiding optimal sampling, interpretation, and reproducibility of results....
20.
Cohen N, Choi D, Choden T, Krugliak Cleveland N, Cohen R, Rubin D
Clin Gastroenterol Hepatol
. 2022 Apr;
21(9):2407-2409.e2.
PMID: 35381385
Ulcerative colitis (UC) is a chronic inflammatory condition affecting the colon and rectum. Long-term therapy is generally required to achieve and maintain disease control. In May 2021 the US Food...